Information:
Fel:
ID
32706
Beskrivning
Study ID: 107038 Clinical Study ID: LPL107038 Study Title: Study to Estimate the Dose Proportionality of the Enteric-Coated Freebase Formulation of SB-480848 Patient Level Data: Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: darapladib Trade Name: Tyrisa ,US Study Indication: Atherosclerosis
Nyckelord
Versioner (1)
- 2018-11-13 2018-11-13 -
Rättsinnehavare
GSK group of companies
Uppladdad den
13 november 2018
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Estimation of Dose Proportionality of Darapladib - 107038
Logs and Repeats: General Adverse Event and Concomitant Medication Questions
Similar models
Logs and Repeats: General Adverse Event and Concomitant Medication Questions
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Date below is the start of the study for this subject
Item
Date below is the start of the study for this subject
date
Item Group
Adverse Event/Concomitant Medications/Repeat Assessment (Check Questions)
Were any concomitant medications taken by the subject during the study?
Item
Were any concomitant medications taken by the subject during the study?
boolean
Did the subject experience any adverse events during the study?
Item
Did the subject experience any adverse events during the study?
boolean
Were any repeat ECGs performed?
Item
Were any repeat ECGs performed?
boolean
Were any repeat/unscheduled PK samples taken?
Item
Were any repeat/unscheduled PK samples taken?
boolean
Were any repeat/unscheduled PD samples taken?
Item
Were any repeat/unscheduled PD samples taken?
boolean